



PTO/SB/08a/b (07-05)
 Approved for use through 07/31/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/625,073-Conf. #9446		
		Filing Date	July 22, 2003		
		First Named Inventor	Mark I. Greene		
		Art Unit	1617		
		Examiner Name	L. M. Williams		
Sheet	1	of	1	Attorney Docket Number	20273/100K201-US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/LW/	BA	WO-01/08699-A1	02-08-2001	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Leonard Williams/ (08/28/2007)	Date Considered	
-----------------------	---------------------------------	--------------------	--



Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/625,073
				Filing Date	July 22, 2003
				First Named Inventor	Mark I. Greene
				Art Unit	1653
				Examiner Name	A. A. Mohamed
Sheet	1	of	1	Attorney Docket Number	04040/100K201-US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
/LW/	BA	WO-00/15807-A1	03-23-2000	Halkier et al.		
/LW/	BB	WO-00/01349-A2	01-13-2000	Murali et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Leonard Williams/ (08/28/2007)	Date Considered	
-----------------------	---------------------------------	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete If Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Mark I. Greene
				Art Unit	1653
				Examiner Name	A. Mohamed
Sheet	1	of	3	Attorney Docket Number	4040/1K201US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/LW/	AA	4,215,051	7/29/80	Schroeder et al.	
	AB	4,946,778	8/7/90	Ladner et al.	
	AC	5,470,952	11/28/95	Stahl et al.	
	AD	5,849,865	12/15/98	Cheng et al.	
	AE	5,955,425	9/21/99	Morley et al.	
	AF	5,985,832	11/16/99	Roodman et al.	
/LW/	AG	5,869,452	2/9/99	Ng et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
/LW/	AH	EP 0 045 665	5/8/81			
/LW/	AI	WO 98/53842	12/3/1998			
/LW/	AJ	WO 99/58674	11/18/99			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/LW/	AK	Ahmed et al., The Journal of Biological Chemistry, 250(21):8477-8482, November 1975			
↓	AL	Albericio et al., Int. J. Peptide Protein Res. 26:92-97, 1985			
	AM	Anderson et al. Nature, Vol. 390, pp. 175-179, November 13, 1997			
	AN	Banner et al., Cell, 73:431-445, May 1993			
	AO	Beutler et al., Science, 264:667-668, April 1994			
	AP	Beutler et al., Annals of The New York Academy of Sciences, 730:118-133, 1994			
	AQ	Bowie et al. Science, Vol. 247, pp. 1306-1310, 1990			
	AR	Brisson et al., Nature, 310:511-514, August 1984			
	AS	Broglie et al., Science 224:838-843, May 1984			
	AT	Bucay et al., Genes Dev., 12(9):1260-1268, 1998			
	AU	Cole et al., Monoclonal Antibodies and Cancer Therapy, 77-96, January-February 1985			
	AV	Coruzzi et al., The EMBO Journal 3(8):1671-1679			
	AW	Cote et al., Proc. Natl. Acad. Sci. USA, 80:2026-2030, 1983			
	AX	Döring et al., Molecular Immunology, 31(14):1059-1067, 1994			
	AY	Filvaroff, Current Biology, 8:R679-682, 1998			
	↓				
/LW/	AZ	Fox et al. Biochem. Biophys. Res. Comm., Vol. 276, pp. 868-872, 2000			

Examiner Signature	/Leonard Williams/ (08/28/2007)	Date Considered	
--------------------	---------------------------------	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	Not Yet Assigned	
			Filing Date	Concurrently Herewith	
			First Named Inventor	Mark I. Greene	
			Art Unit	1653	
			Examiner Name	A. Mohamed	
Sheet	2	of	3	Attorney Docket Number	4040/1K201US2

/LW/	BA	Fingl et al., "General Principles," In: The Pharmacological Basis of Therapeutics, Chapter 1, 1-46, 1975	
	BB	Fuller, K., et al., "TRANCE is necessary and sufficient for osteoblastmediated activation of bone resorption in osteoclasts," <i>Database Chemical Abstracts on STN, No. 129:314804</i> , Abstract, <i>J. Exp. Med.</i> , 1998, 188(5), 997-1001	
	BC	Gruss et al., <i>Cytokines and Molecular Therapy</i> 1:75-105, May 1995	
	BD	Gurley, et al., <i>Molecular and Cellular Biology</i> , 6:559-565, February 1986	
	BE	Habeeb, A.F.S.A., <i>Analytical Biochemistry</i> , 56:60-65, 1973	
	BF	Hann et al., <i>J. Chem. Soc. Perkin Trans.</i> , 1, 307-314, 1982	
	BG	Holladay et al. <i>Tetrahedron Letters</i> , 24(41):4401-4404, 1983	
	BH	Houghten et al. <i>Cell</i> , Vol. 93, pp. 165-176, April 17, 1998	
	BI	Houghten et al., <i>Vaccines</i> 86, Cold Spring Harbor Laboratory, pp. 21-25, 1986	
	BJ	Hruby et al., <i>Life Sciences</i> , 31:189-199, 1982	
	BK	Hudson et al. <i>Int. J. Protein Res.</i> , 14:177-185, 1979	
	BL	Huse, et al., <i>Science</i> , 246:1275-1281, December 1989	
	BM	Jennings-White et al., <i>Tetrahedron Letters</i> , 23(25):2533-2534, 1982	
	BN	Kamber et al., <i>Helvetica Chimica Acta</i> , 63(Fasc. 4):899-915, 1980	
	BO	Kobayashi et al., <i>J. Exp. Med.</i> , Vol. 191, No. 2, 275-285, 2000	
	BP	Köhler et al., <i>Nature</i> , 256:495-497, 1975	
	BQ	Kong et al., <i>Immunology and Cell Biology</i> , 77:188-193, January 1999	
	BR	Kong et al., <i>Nature</i> , 397:315-323, 1999	
	BS	Kornak et al., <i>Cell</i> , 104:205-215, 2001	
	BT	Kozbor et al., <i>Immunology Today</i> , 4(3):72-79, 1983	
	BU	Lacey et al., <i>Amer. J. of Pathology</i> , 157(2):435-448, 2000	
	BV	Li Y.P. et al., <i>Nature Genetics</i> , 23:447-451, 1999	
	BW	Li J. et al., <i>PNAS</i> , 97(4):1566-1571, 2000	
	BX	Livingstone, David M., <i>Methods in Enzymology, Affinity Techniques</i> , 723-731, 1974	
	BY	Logan et al., <i>Proc. Natl. Acad. Sci. USA</i> , 81:3655-3659, June 1984	
	BZ	Mackett et al., <i>Proc. Natl. Acad. Sci. USA</i> 79:7415-7519, December 1982	
	CA	Mackett et al., <i>Journal of Virology</i> , 49(3):857-864, March 1984	
	CB	McOsker et al., <i>J. Bone & Mineral Research</i> , Twelfth Annual Meeting of the American Society for Bone and Mineral Research, 5(Suppl 2):S105, No. 128, Abstract, Aug. 28-31, 1990	
	CC	Moore et al., <i>Techniques in Protein Chemistry VII</i> , Marsak (ed.) 81-91, 1996	
	CD	Morley, J.S., <i>Trends Pharm. Sci.</i> , 463-468, December 1980	
	CE	Morrison et al., <i>Proc. Natl. Acad. Sci. USA</i> , 81:6851-6855, November 1984	
	CF	Mortensen et al., <i>J. Clinical Endocrinology and Metabolism</i> , 83(2):396-402, 1998	
	CG	Nakagawa, N., et al., "RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis" <i>Database Chemical Abstracts on STN, No. 130:166173</i> , Abstract, <i>Biochem. Biophys. Res. Commun.</i> , 1998, 253(2), 395-400	
	CH	Neuberger et al., <i>Nature</i> , 312:604-608, December 1984	
	CI	Nicholson et al., <i>J. Clinical Investigation</i> , 78:355-360, August 1986	
	CJ	Panicali et al., <i>Proc. Natl. Acad. Sci. USA</i> , 79:4927-4931, August 1982	
	CK	Peppel et al., <i>J. Exp. Med.</i> , 174:1483-1489, December 1991	
	CL	Ponder et al., <i>J. Mol. Biol.</i> , 193:775-791, 1987	
	CM	Scimeca, J.C., <i>Bone</i> , 26(3):207-213, 2000	
/LW/	CN	Shalhoub, V. et al., <i>British J. of Haematology</i> , 111:501-512, 2000	

Examiner Signature	/Leonard Williams/ (08/28/2007)	Date Considered	
--------------------	---------------------------------	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete If Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Mark I. Greene
				Art Unit	1653
				Examiner Name	A. Mohamed
Sheet	3	of	3	Attorney Docket Number	4040/1K201US2

/LW/	CO	Shalhoub et al., J. Cellular Biochem., 72(2):251-261, 1999	
	CP	Sietsema et al., Drugs Exptl. Clin. Res., XV(9):389-396, 1989	
	CQ	Simonet et al., Cell, 89(2):309-319, 1997	
	CR	Singer et al., J. Clinical Endocrinology and Metabolism, 83(6):1906-1910, 1998	
	CS	Siris et al., J. Bone and Mineral Research, 13(6):1032-1038, 1998	
	CT	Smith et al., Journal of Virology, 46:584-593, May 1983	
	CU	Spatola, A. F., Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, 7:267-357, 1983	
	CV	Spatola et al., Life Sciences, 38:1243-1249, 1986	
	CW	Suda et al., Endocrine Reviews 20(3):345-357, June 1999	
	CX	Suda et al., Novartis Found Symp, 232: 235, 2001 (Abstract)	
	CY	Takamatsu et al., EMBRO Journal, 6(2):307-311, 1987	
	CZ	Takasaki et al., Nature Biotechnology, 15:1266-1270, 1997	
	DA	Takeda et al., Nature 314:452-454, 1985	
	DB	Tam et al., Synthesis, 955-957, December 1979	
	DC	Van Beck E., J. Bone and Mineral Research, 11(10):1492-1497, 1996	
	DD	Weitzmann et al., J. of Bone and Mineral Research, 16(2):328-337, 2001	
	DE	Williams et al., Immunology, 84:433-439, 1995	
	DF	Wong et al. Journal of Leukocyte Biology, 65:715-724, June 1999	
	DG	Yamaguchi et al., J. of Biological Chemistry, 273(9):5177-5123, Feb. 28, 1998	
✓	DH	Yasuda et al. Proc. Natl. Acad. Sci. USA., Vol. 95 pp. 3597-3602, March 1998	
	DI	Zhang et al., Nature Biotechnology, 14:472-475, April 1996	
/I W/	DJ	Zhang et al., Nature Biotechnology, 15:150-154, 1997	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Leonard Williams/ (08/28/2007)	Date Considered	
-----------------------	---------------------------------	--------------------	--